Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Method of treating asthma with antiviral agents

An antiviral agent, a technology for asthma, applied in the field of asthma treatment, can solve problems such as unsuitability for maintenance treatment and pulmonary function decline

Inactive Publication Date: 2012-07-11
MUTUAL PHARMA CO INC
View PDF41 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Continuous treatment of asthmatic patients with the bronchodilators ipratropium bromide or fenoterol resulted in a faster decline in lung function compared with as-needed treatment, suggesting that these drugs are not suitable for maintenance therapy

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Method of treating asthma with antiviral agents
  • Method of treating asthma with antiviral agents

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0093] An adult male with a history of asthma has been taking inhaled steroids and beta 2 - Agonist for many years, with mixed results. he used to use inhaled twice daily, or Spray four times a day. is a drug containing fluticasone propionate (a corticosteroid) and salmeterol xinafoate (a long-acting beta 2 - combination preparations of adrenergic receptor agonists). Contains two active ingredients delivered through a single inhaler: budesonide - a corticosteroid, and formoterol - a long-acting beta 2 - Agonists. His peak flow is at best 600-650 L / min, but will degenerate to around 250-350 L / min during exacerbations, and usually drops below 550 L / min when not having seizures. Over the years, he required occasional treatment with oral prednisone, a corticosteroid. Exercise tolerance was moderate to poor.

[0094] He exhibited flu-like symptoms and was started on Tamiflu 75mg, twice a day for 5 days. Within 12 hours, he began to feel better and his myalgia decreas...

Embodiment 2

[0095] Embodiment 2 oseltamivir phosphate (tamiflu ) randomized, double-blind, placebo-controlled evaluation in patients with poorly controlled asthma

[0096] Current asthma guidelines emphasize asthma control. One aspect of control is the current burden indicated by symptom levels, rescue medication use, nighttime awakenings, and interference with normal activities. Patients who did not meet the specified goals were considered to have "not well controlled asthma". The guidelines further recommend treatment steps to achieve control. For many patients, these measures are sufficient to achieve asthma control, but for at least 30% of patients, even optimal doses of inhaled corticosteroids and long-acting beta-agonists sustained for one year were not achieved in the GOAL study Control (Bateman et al., Can guideline defined asthma control be achieved? The Gaining Optimal Asthma Control study. Am J Respir Crit Care Med2004;170:836-44). Therefore, there is a need to identify ...

Embodiment 3

[0165] Twelve patients with asthma were given an appropriate dose, e.g., the Prescribing Information (PI) dose of oseltamivir phosphate (Tamiflu )treat. Patients can be randomized into several groups: the high-dose group will receive oseltamivir 150 mg twice daily or an equivalent dose adjusted for age, weight, and renal function for 5-10 days; the medium-dose group will receive oseltamivir twice daily 110 mg of oseltamivir or an equivalent dose adjusted according to age, weight and renal function for 5-10 days; the standard dose group will receive 75 mg of oseltamivir twice a day or an equivalent dose adjusted according to age, weight and renal function for 5-10 days sky. http: / / clinicaltrials.gov / ct2 / show / NCT00298233.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
diameteraaaaaaaaaa
Login to View More

Abstract

The present invention provides a method of treating asthma by administering a therapeutically effective amount of an antiviral agent to a patient. The antiviral agent may be a neuraminidase inhibitor, a viral fusion inhibitor, a protease inhibitor, a DNA polymerase inhibitor, a signal transduction inhibitor, a nucleoside reverse transcriptase inhibitor (NRTI), a non-nucleoside reverse transcriptase inhibitor (NNRTI) or an interferon. The antiviral agent may be administered to the patient by inhalation, nasally, intravenously, orally, subcutaneously, intramuscularly or transdermally. For example, the antiviral agent may be formulated for delivery as aerosols to the patient.

Description

[0001] Cross References to Related Applications [0002] This application claims priority under 35 U.S.C. §119(e) to U.S. Provisional Application 61 / 243,449, filed September 17, 2009. field of invention [0003] The present invention relates to a pharmaceutical composition comprising an antiviral agent and a method of treating asthma using the pharmaceutical composition. Background of the invention [0004] Asthma is a chronic lung disease characterized by bronchoconstriction, airway inflammation, and excess mucus production, all of which lead to airway obstruction. Asthma symptoms include shortness of breath (dyspnea), wheezing, chest tightness and cough, which can be life-threatening or even fatal (The Merck Manual, 556-568 (17th Ed., 1999)). People with asthma also have increased sensitivity of the airways to a variety of stimuli, such as allergens, chemical irritants, air pollutants, respiratory infections, cold air, and physical activity. Thus, asthma is further chara...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/19A61K9/12
CPCA61K38/21A61K31/215A61P11/06A61P31/12A61K2300/00
Inventor R·H·罗伯斯
Owner MUTUAL PHARMA CO INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com